N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

European Journal of Clinical Pharmacology

Volumn 70, Issue 9, 2014, Pages 1079-1086

  Ng, Ching Soon ^a,b   Hasnat, Abul ^c   Al Maruf, Abdullah ^c   Ahmed, Maizbha Uddin ^c   Pirmohamed, Munir ^d   Day, Christopher P ^a   Aithal, Guruprasad P ^e   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY OF DHAKA   (Bangladesh)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Acetylation; Antituberculosis drugs; Drug induced liver injury; Isoniazid; NAT2; Pharmacogenetics

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN PLUS ETHAMBUTOL; UNCLASSIFIED DRUG; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; ARYLAMINE ACETYLTRANSFERASE GENE; ASIAN; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ETHNICITY; EUROPE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; TUBERCULOSIS; ASIA; CASE CONTROL STUDY; DRUG COMBINATION; DRUG-INDUCED LIVER INJURY; ETHNIC GROUP; GENETIC PREDISPOSITION; GENETICS; ODDS RATIO;

ADULT; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIA; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; ETHNIC GROUPS; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TUBERCULOSIS;

EID: 84906237311     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1703-0     Document Type: Article

References (48)

1. Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9(10):2026-2030 (Pubitemid 26333539)
2. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeisson UP, Timbrell JA, Snodgrass WR, Nelson SD (1976) Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84:181-192
3. Scharer L, Smith JP (1969) Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 71(6):1113-1120
4. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89(6):806-815
5. Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvani A, Wickremasinghe M, Kon OM (2012) A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 185(6):653-659
6. Steele MA, Burk RF, DesPrez RM (1991) Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99(2):465-471
7. Eichelbaum M, Musch E, Castroparra M, Vonsassen W (1982) Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J Clin Pharmacol 14(4):P575-P576
8. Sarich TC, Adams SP, Petricca G, Wright JM (1999) Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 289(2):695-702 (Pubitemid 29191221)
9. Gronhagen-Riska C, Hellstrom PE, Froseth B (1978) Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 118(3):461-466 (Pubitemid 9027187)
10. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM (1981) Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 3(3):271-279 (Pubitemid 11053230)
11. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18(1):70-79
12. Daly AK, Day CP (2012) Genetic association studies in drug-induced liver injury. Drug Metab Rev 44(1):116-126
13. Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, Li X, Tu D, Chen Y, Deng P, Ma Y, Chen D, Chen R, Zhan S (2012) NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol 11(5):700-707
14. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuber Lung Dis 4(3):256-261 (Pubitemid 30151575)
15. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4):883-889
16. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, Lee SY (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87(6):551-556
17. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, Song J, Kim SH, Park HS, Min KU, Jee YK (2009) Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10(11):1767-1779
18. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS (2010) NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuber Lung Dis 14(5):622-626
19. Ho HT, Wang TH, Hsiong CH, Perng WC, Wang NC, Huang TY, Jong YJ, Lu PL, Hu OY (2013) The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics 23(4):200-207
20. An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y (2012) NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 39(6):535-543
21. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I (2013) NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69(5):1091-1101
22. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RL, Gregianini TS, Hutz MH, Rossetti ML, Zaha A (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64(7):673-681
23. Bozok Cetintas V, Erer OF, Kosova B, Ozdemir I, Topcuoglu N, Aktogu S, Eroglu Z (2008) Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 56(1):81-86
24. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, Botana-Rial M, Constenla L, Agundez JA, Fernandez-Villar A (2011) N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuber Lung Dis 15 (10):1403-1408
25. Rana SV, Ola RP, Sharma SK, Arora SK, Sinha SK, Pandhi P, Singh K (2012) Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients. Hepatol Int 6:397-402
26. Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H, Hammami S, Sahnoun Z, Zalila N, Makni H, Zeghal K (2012) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol (Paris) 60(5):324-330
27. Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frias A, Visca M, Aidar O, Peres S, de Larranaga GF (2013) Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 28(2):323-328
28. Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, de Carvalho DC, Santos SE, Hutz MH (2013) N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuber Lung Dis 17(4):499-504
29. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Ramegowda PH, Amarapurkar AD, Joshi K, Wangikar PP (2013) Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 28(8):1368-1374
30. Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, Hirata RD (2013) Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta 415:215-219
31. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62(6):423-429 (Pubitemid 44069498)
32. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F (2009) Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10(9):1433-1445
33. Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, Wang Q, Ma J, Cao M, Wang Q, Yao X, Yang L, Wubuli A, Merle C, Milligan P, Mao Y, Gu J, Xin X (2014) The incidence of liver injury in uyghur patients treated for TB in Xinjiang Uyghur Autonomous Region, China, and its association with hepatic enzyme polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. PLoS ONE 9(1):e85905
34. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174(8):935-952 (Pubitemid 44564795)
35. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP (2005) High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 26(3):462-464 (Pubitemid 41264210)
36. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M (2002) Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 167(2):131-136 (Pubitemid 34791519)
37. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:816-819
38. Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46(11):1323-1330 (Pubitemid 23333873)
39. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, Pearce SH (2004) The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 89(11):5862-5865 (Pubitemid 39518482)
40. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE (2004) N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population. Int J Toxicol 23(1):25-31 (Pubitemid 38332444)
41. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB (2012) Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 22 (11):784-795
42. Garcia-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, Doll MA, Figueroa JD, Baris D, Schwenn M, Kogevinas M, Johnson A, Chatterjee N, Moore LE, Moeller T, Real FX, Chanock S, Rothman N (2011) A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 21 (4):231-236
43. Metushi IG, Sanders C, Lee WM, Uetrecht J (2013)Detection of anti-isoniazid and anti-cyp antibodies in patients with isoniazid-induced liver failure. Hepatology
44. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK (2002) Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166(7):916-919 (Pubitemid 35193218)
45. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, Day CP (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39(5):1430-1440 (Pubitemid 38569066)
46. Selinski S, Blaszkewicz M, Lehmann ML, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thuroff JW, Angeli-Greaves M, Seidel T, Roth G, Dietrich H, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Lohlein D, Weistenhofer W, Schops W, Hassan Rizvi SA, Aslam M, Banfi G, Romics I, Steffens M, Ekici AB, Winterpacht A, Ickstadt K, Schwender H, Hengstler JG, Golka K (2011) Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 21(10):673-678
47. Suarez-Kurtz G, Sortica VA, Vargens DD, Bruxel EM, Petzl-Erler ML, Tsuneto LT, Hutz MH (2012) Impact of population diversity on the prediction of 7-SNP NAT2 phenotypes using the tagSNP rs1495741 or paired SNPs. Pharmacogenet Genomics 22(4):305-309
48. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sorgel F, Fuhr U (2005) Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49(5):1733-1738 (Pubitemid 40631582)